Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

Bet9ja live Eglin Pharmaceuticals launches Phase 1 clinical trial of oral candidate drug for CRS caused by COVID-19 Senior rehabilitation therapists are not ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

T he treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients ...

The draw, held earlier this week, required candidates to have a minimum Comprehensive Ranking System (CRS) score of 727. This marks the third Express Entry draw of December. The first, on December 2, ...

Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth ...

In 2010, a private-equity firm called Cerberus Capital Management, which is named for the three-headed dog that is said to guard the underworld, bought six Catholic hospitals in Massachusetts and ...

Billionaire investor and businessman Mark Cuban recently met with leaders at Penn Medicine, including University of Pennsylvania Health System CEO Kevin Mahoney (left) and Penn Medicine vice president ...

Non-relapse mortality (NRM) did not differ significantly. Severe cytokine release syndrome (CRS) occurred more than twice as often with cilta-cel, although the rate was low in both groups.